日本老年人接种水痘疫苗预防带状疱疹及带状疱疹后神经痛的成本效果分析
本研究采用马尔可夫模型,从社会视角评估日本65-84、70-84、75-84和80-84岁四个年龄段老年人接种水痘疫苗预防带状疱疹及带状疱疹后神经痛的成本效果。结果显示各策略的增量成本效果比(ICER)范围为¥2,812,000/25,680美元至¥3,644,000/33,279美元每获得一个质量调整生命年(QALY),其中65-84岁策略ICER最低。概率敏感性分析显示,各策略ICER低于¥5,000,000/45,662美元每QALY的概率分别为100%、100%、100%和98.4%,65-84岁策略为最优方案。
要点
- 65-84岁策略ICER最低(¥2,812,000/25,680美元每QALY),为最优方案。
- 80-84岁策略ICER最高(¥3,644,000/33,279美元每QALY)。
- 所有策略ICER低于¥5,000,000/45,662美元每QALY的概率均较高。
核心结论
- 在日本,对65-84、70-84、75-84和80-84岁人群接种水痘疫苗预防带状疱疹相关疾病,从社会视角具有成本效果,其中65-84岁策略为最优方案。
研究设计与样本
- 采用马尔可夫模型进行成本效果分析,评估日本老年人水痘疫苗接种规划的效率。
- 设定四种接种年龄策略:65-84岁、70-84岁、75-84岁和80-84岁。
- 从社会视角计算与不接种规划相比的增量成本效果比(ICER)。
- 每剂疫苗接种成本假设为¥10,000(91美元),模型周期为1年,运行至存活个体达到100岁。
主要发现
- ICER范围为¥2,812,000/25,680美元至¥3,644,000/33,279美元每QALY获得,65-84岁策略ICER最低,80-84岁策略最高。
- 各策略间无强优势,但80-84岁和70-84岁策略被65-84岁策略扩展优势。
- 概率敏感性分析显示,ICER低于¥5,000,000/45,662美元每QALY获得的概率在65-84岁、70-84岁、75-84岁策略均为100%,在80-84岁策略为98.4%。
关键数值与推荐
- ICER范围:¥2,812,000/25,680美元至¥3,644,000/33,279美元每QALY获得。
- 65-84岁策略ICER最低,80-84岁策略ICER最高。
- ICER低于¥5,000,000/45,662美元每QALY获得的概率:65-84岁、70-84岁、75-84岁策略均为100%,80-84岁策略为98.4%。
临床怎么用
- 作者认为,在日本对65-84岁人群接种水痘疫苗预防带状疱疹相关疾病从社会视角具有成本效果,且为最优策略。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The extended use of varicella vaccine in adults aged 50 and older against herpes zoster (HZ) was recently approved in Japan, which has raised the need to evaluate its value for money. METHODS: We conducted a cost-effectiveness analysis with Markov modelling to evaluate the efficiency of varicella vaccine immunisation programme for the elderly in Japan. Four strategies with different ages to receive a shot of vaccine were set, namely: (1) 65-84, (2) 70-84, (3) 75-84 and (4) 80-84years old (y.o.). Incremental cost-effectiveness ratios (ICERs) compared with no programme from societal perspective were calculated. The health statuses following the target cohort are as follows: without any HZ-related disease, acute HZ followed by recovery, post-herpetic neuralgia (PHN) followed by recovery, post HZ/PHN, and general death. The transition probabilities, utility weights to estimate quality-adjusted life year (QALY) and disease treatment costs were either calculated or cited from literature. Costs of per course of vaccination were assumed at ¥10,000 (US$91). The model with one-year cycle runs until the surviving individual reached 100 y.o. RESULTS: ICERs ranged from ¥2,812,000/US$25,680 to ¥3,644,000/US$33,279 per QALY gained, with 65-84 y.o. strategy having the lowest ICER and 80-84 y.o. strategy the highest. None of the alternatives was strongly dominated by the other, while 80-84 y.o. and 70-84 y.o. strategy were extendedly dominated by 65-84 y.o. STRATEGY: Probabilistic sensitivity analyses showed that the probabilities that ICER is under ¥5,000,000/US$45,662 per QALY gained was at 100% for 65-84 y.o., 70-84 y.o., 75-84 y.o. strategy, respectively, and at 98.4% for 80-84 y.o. CONCLUSION: We found that vaccinating individuals aged 65-84, 70-84, 75-84, and 80-84 with varicella vaccine to prevent HZ-associated disease in Japan can be cost-effective from societal perspective, with 65-84 y.o. strategy as the optimal alternative. Results are supported by one-way sensitivity analyses and probabilistic sensitivity analyses.
引用
- Hoshi SL, Kondo M, Okubo I, et al. Cost-effectiveness of varicella vaccine against herpes zoster and post-herpetic neuralgia for elderly in Japan. Vaccine. 2017. PMID: 28479176. doi:10.1016/j.vaccine.2017.04.046
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。